SCHEMBL2966450

SCHEMBL2966450

Cc1ccc(Sc2ccc(O)cc2)c(Nc2cc(C)nc3nc(C)ccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.47
AKT2 P31751 1/20 0.47
KDM4E B2RXH2 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GFER P55789 2/20 0.34
KMT2A Q03164 6/20 0.33
MEN1 O00255 5/20 0.33
POLB P06746 3/20 0.33
RAD52 P43351 2/20 0.33
BLM P54132 2/20 0.33
GAA P10253 2/20 0.33
PAX8 Q06710 1/20 0.33
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
MITF O75030 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2015588 0.88 PIM1 (0.49) PIM1AKT2KDM4EKMT2AMEN1
SCHEMBL811431 0.82 PIM1 (0.66) PIM1AKT2KDM4EKMT2AMEN1
SCHEMBL2968986 0.80 PIM1 (0.41) PIM1AKT2KDM4EL3MBTL1BLM
SCHEMBL13330161 0.79 PIM1 (0.49) PIM1AKT2KMT2AMEN1GAA
SCHEMBL2021349 0.77 PIM1 (0.40) PIM1AKT2KDM4EKMT2AMEN1
SCHEMBL2968944 0.76 PIM1 (0.39) PIM1AKT2KDM4EL3MBTL1KMT2A
SCHEMBL2022784 0.76 PIM1 (0.39) PIM1AKT2KDM4EL3MBTL1GAA
SCHEMBL2019804 0.76 PIM1 (0.41) PIM1AKT2KDM4EKMT2AMEN1
SCHEMBL2021057 0.76 PIM1 (0.41) PIM1AKT2GFERKMT2AMEN1
SCHEMBL13273751 0.76 PIM1 (0.47) PIM1AKT2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885KDM4E 1822/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885KDM4E 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.